Abstract
TP53 and phosphate and tension homolog (PTEN) are two tumor suppressor genes that regulate cell proliferation, migration, and death. P53 and PTEN deficiency has been associated with hepatic fibrosis, a prominent pathological feature associated with chronic hepatitis B (CHB). The present study is aimed to assess the association of PTEN 32-bp Ins/Del (rs34421660) and TP53 16-bp Ins/Del polymorphisms with CHB infection susceptibility. A total of 411 subjects were recruited in this case–control study of 213 patients with CHB infection and 198 healthy individuals as controls. PTEN and TP53 deletions were detected by polymerase chain reaction method. We found no significant association between PTEN 32-bp Ins/Del polymorphism and the risk for CHB using either of codominant (Ins/Del vs. Ins/Ins: P = 0.427; Del/Del vs. Ins/Ins: P = 0.235), dominant (Ins/Del + Del/Del vs. Ins/Ins P = 0.343) or recessive genetic model (Del/Del vs. Ins/Ins + Ins/Del: P = 0.516). At allelic level although the PTEN Del variant allele was more common in CHB patients compared to controls (55 vs. 51), but the difference did not reach the statistical significant range (OR 0.87, P = 0.327). Similarly, no association was observed between TP53 16-bp Ins/Del and the risk for CHB infection at both genotype and allele levels (P > 0.05). In summary, our study demonstrated that the PTEN 32-bp and TP53 16-bp Ins/Del polymorphisms did not affect the risk of CHB infection in the Iranian population.
Similar content being viewed by others
Change history
08 December 2017
In the original publication, the corresponding author’s city name was incorrectly published in the affiliation section. The correct information is given below. 5Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, Islamic Republic of Iran.
References
Abbott W, et al. Polymorphism in intron 1 of the interferon-gamma gene influences both serum immunoglobulin E levels and the risk for chronic hepatitis B virus infection in Polynesians. Immunogenetics. 2007;59(3):187–95.
Bao W, et al. Loss of nuclear PTEN in HCV-infected human hepatocytes. Infect Agent Cancer. 2014;9:23.
Birerdinc A, et al. Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C). J Viral Hepat. 2012;19(6):414–22.
Chang MH. Hepatitis B virus infection. Semin Fetal Neonatal Med. 2007;12(3):160–7.
Chung TW, et al. Hepatitis B Virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells. Cancer Res. 2003;63(13):3453–8.
Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J. 2004;18(10):1123–5.
de Andrade DR Jr, de Andrade DR. The influence of the human genome on chronic viral hepatitis outcome. Rev Inst Med Trop Sao Paulo. 2004;46(3):119–26.
Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359(14):1486–500.
Ding J, et al. Association of PTEN polymorphisms with susceptibility to hepatocellular carcinoma in a Han Chinese population. DNA Cell Biol. 2011;30(4):229–34.
Du Y, et al. Phosphatase and tensin homologue genetic polymorphisms and their interactions with viral mutations on the risk of hepatocellular carcinoma. Chin Med J (Engl). 2015;128(8):1005–13.
Eskandari-Nasab E, et al. Effect of TP53 16-bp and beta-TrCP 9-bp INS/DEL polymorphisms in relation to risk of breast cancer. Gene. 2015;568(2):181–5.
Hashemi M, et al. Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genet Mol Res. 2010;9(1):333–9.
Hashemi M, et al. Association of promoter methylation and 32-bp deletion of the PTEN gene with susceptibility to metabolic syndrome. Mol Med Rep. 2013;7(1):342–6.
Hashemi M, et al. Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer. Oncol Lett. 2017;13(4):2483–9.
Horie Y, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 2004;113(12):1774–83.
Hu S, et al. The association between polymorphism of P53 codon 72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3704 cases. Meta Gene. 2013;1:126–37.
Kang-Park S, et al. PTEN modulates hepatitis B virus-X protein induced survival signaling in Chang liver cells. Virus Res. 2006;122(1–2):53–60.
Laaribi AB, et al. Association of an HLA-G 14-bp Insertion/Deletion polymorphism with high HBV replication in chronic hepatitis. J Viral Hepat. 2015;22(10):835–41.
Lai CL, et al. Viral hepatitis B. Lancet. 2003;362(9401):2089–94.
Lebok P, et al. Partial PTEN deletion is linked to poor prognosis in breast cancer. BMC Cancer. 2015;15:963.
Li HG, et al. Association of PTEN gene polymorphisms with liver cancer risk. Int J Clin Exp Pathol. 2015;8(11):15198–203.
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507–39.
Mah YH, et al. Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. Hepatol Int. 2011;5(3):814–21.
Matsuda S, Kobayashi M, Kitagishi Y. Roles for PI3K/AKT/PTEN pathway in cell signaling of nonalcoholic fatty liver disease. ISRN Endocrinol. 2013;2013:472432.
Peyrou M, Bourgoin L, Foti M. PTEN in liver diseases and cancer. World J Gastroenterol. 2010;16(37):4627–33.
Peyrou M, Bourgoin L, Foti M. PTEN in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and cancer. Dig Dis. 2010;28(1):236–46.
Shearn CT, et al. Increased carbonylation of the lipid phosphatase PTEN contributes to Akt2 activation in a murine model of early alcohol-induced steatosis. Free Radic Biol Med. 2013;65:680–92.
Steck PA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15(4):356–62.
Szpakowski JL, Tucker LY. Causes of death in patients with hepatitis B: a natural history cohort study in the United States. Hepatology. 2013;58(1):21–30.
Wang L, et al. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res. 2007;37(5):389–96.
Zampino R, et al. Hepatitis B virus burden in developing countries. World J Gastroenterol. 2015;21(42):11941–53.
Zhang TC, et al. A meta-analysis of the relation of polymorphism at sites -1082 and -592 of the IL-10 gene promoter with susceptibility and clearance to persistent hepatitis B virus infection in the Chinese population. Infection. 2011;39(1):21–7.
Acknowledgements
The authors are grateful for the cooperation of all individuals who voluntarily took part in the present study. We thank the Research Deputy of Zahedan University of Medical Sciences, Iran for funding this research.
Author information
Authors and Affiliations
Corresponding author
Additional information
A correction to this article is available online at https://doi.org/10.1007/s13337-017-0417-1.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Eskandari, E., Dahmardeh, T., Dahmardeh, F. et al. Lack of relationship between PTEN 32-bp and TP53 16-bp Ins/Del polymorphisms and chronic hepatitis B virus infection. VirusDis. 28, 289–294 (2017). https://doi.org/10.1007/s13337-017-0391-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13337-017-0391-7